Senseonics adopts 2023 Commercial Equity Plan for partner Ascensia employees; up to 10M shares

Senseonics Holdings, Inc.

Board adopted 2023 Commercial Equity Plan on Jan 10, 2023 to grant stock options and RSUs to employees of commercial partner Ascensia Diabetes Care.
Plan reserves 10,000,000 shares of common stock for issuance, subject to performance-based vesting.
Grants require SEC Form S-3 registration statement to be declared effective before awards can be issued.
Plan aims to align incentives of individuals supporting Eversense commercialization with shareholder interests.
Eligible recipients include Ascensia employees assisting with commercialization, who are ineligible for the existing 2015 Equity Incentive Plan.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.